Answers are grounded in this paper and cite their sources.
TAMs are most enriched in individuals with ovarian cancer, where TREM2 expression corresponds to disease grade accompanied by worse recurrence-free survival. In an aggressive orthotopic ovarian cancer model, anti-TREM2 mAb therapy drives potent anti-tumor immunity. These results highlight TREM2 as a highly attractive target for immunotherapy modulation in individuals who are refractory to CPI therapy and likely have a TAM-rich tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Binnewies et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: